The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease and, thus, there are large inter-patient variations in terms of disease course, prognosis, relapse, and resistance to conventional or targeted therapeutics. Our activities are directed towards personalised treatment and range from preclinical models to correlative studies and clinical trials.
Our current research areas are:
- Studying the implications of hypoxia for immunotherapies.
- Understanding the individual factors regulating the response to immunotherapy in breast cancer, taking advantage of an advanced, personalised “tumouroid” platform.
- Tackling the mechanisms of resistance against novel therapies in advanced breast cancer.
- Incorporating our findings into concept-driven clinical trials.